Delivering on their commitment to push the boundaries of science and advance innovation, AstraZeneca has been an early adopter of AI. This global pharmaceutical leader has harnessed AI to speed up drug discovery, identify disease biomarkers, facilitate diagnostics, and more. Now, Generative AI is revolutionizing regulatory submissions, offering new efficiencies and transformative capabilities.

Join this session and AstraZeneca’s Emilie Louvet, Director of Data Products, Digital Regulatory, Regulatory Affairs as she shares her leadership in driving strategic initiatives on next-generation submissions. Learn how AstraZeneca is implementing AI-powered solutions to accelerate submission timelines and enhance regulatory processes, ensuring faster approvals and greater efficiency.

Key Discussion Points:

• Getting Started with AI in Regulatory Submissions: Best practices and key considerations for integrating Generative AI into submission workflows
• Cost Impact of AI-Powered Regulatory Submissions: Understanding the benefits of AI-driven automation
• Trust but Verify: Explore how to maintain accuracy and compliance while leveraging AI’s potential in regulatory submissions.